Pioglitazone vs. Empagliflozin for Pancreatitis-Related Diabetes
This study is comparing two existing medications, pioglitazone (PIO) and empagliflozin (EMPA), to see which is more effective at controlling blood sugar in people who have diabetes along with chronic pancreatitis (CP) or recurrent acute pancreatitis (RAP). Researchers want to understand how these drugs work in this specific group of patients. You might be able to join if you are between 18 and 80 years old and have been diagnosed with CP or RAP and diabetes. The study will look at your Hemoglobin A1c (HbA1c) levels, which show your average blood sugar over time, and other blood sugar measurements to determine which drug is more successful. The study plans to enroll 40 participants, but its current recruitment status is unclear.
- Study design
- This interventional study will compare two different drug treatments, pioglitazone and empagliflozin, in 40 participants. The study does not specify if it is randomized or blinded.
- What's involved
- You would take either pioglitazone or empagliflozin daily for 24 weeks, with potential dose adjustments after 12 weeks based on your HbA1c levels. Your blood sugar levels will be measured at the beginning and throughout the 24-week period.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your blood sugar levels will be monitored from the start of the study up to 24 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus
At a glance
Conditions
Where it's being run
3 sites across 2 statesStudy leadership
- Yogish Kudva · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Hemoglobin A1c (HbA1c)Baseline to 24 weeks
Hemoglobin is a protein within red blood cells. As glucose enters the bloodstream, it binds to hemoglobin, or glycates. The more glucose that enters the bloodstream, the higher the amount of glycated hemoglobin. An HbA1C level below 5.7 percent is considered normal. Reported as percentage of glycated hemoglobin
- Area under curve (AUC) for glucoseBaseline to 24 weeks
Pre-post study difference in AUC for glucose
- AUC for C-peptideBaseline to 24 weeks
Pre-post study difference in AUC for C-Peptide
- AUC for InsulinBaseline to 24 weeks
Pre-post study difference in AUC for Insulin
- AUC for glucagonBaseline to 24 weeks
Pre-post study difference in AUC for glucagon